WEBULL
WebtradeDownload

Alumis (ALMS), What Is Behind The Fresh Attention?

Simply Wall St · 1d ago

Alumis (ALMS) has just reported that envudeucitinib missed the primary and secondary endpoints in its Phase 2b LUMUS lupus trial, while a high interferon gene signature subgroup showed strong responses, keeping biomarker focused Phase 3 discussions on the table.

Alumis shares have been under pressure around this update, with the 30-day share price return down 60.98% and the 7-day move down 12.85%, even though the 1-year total shareholder return is very large at 127.06%. This suggests earlier optimism is being reassessed in light of the LUMUS data and upcoming conference presentations.

Stress test your thesis on Alumis by comparing it with 39 healthcare AI stocks that are also working on data driven approaches to complex diseases.

Alumis now trades near US$9.90 while the average analyst target sits above US$32. With that kind of gap on the table, where does fair value really belong after LUMUS?

Preferred Price-to-Book Multiple of 2.8x: Is it justified?

Alumis now trades at a price-to-book ratio of 2.8x, which current data classifies as expensive compared with the broader US Pharmaceuticals industry but cheaper than a tight peer set.

P/B compares the market value of the equity to its accounting book value. For a clinical stage biopharma like Alumis that is still loss making, this metric often reflects how the market weighs the pipeline, cash position, and future revenue potential rather than current earnings power.

On industry comparison, the 2.8x P/B sits above the sector average of 2.4x. This indicates investors are assigning a richer tag than the typical US Pharmaceuticals stock. At the same time, that same 2.8x level is described as good value versus a peer group average of 25.9x. This points to a large gap between how Alumis is valued and how some similar development stage businesses are priced.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 2.8x (ABOUT RIGHT)

Still, the LUMUS miss, ongoing losses of US$438.957 million and dependence on clinical trial milestones could all work against the current Alumis valuation narrative.

Find out about the key risks to this Alumis narrative.

Next Steps

Mixed reactions around Alumis are already showing up in the share price. Move quickly, pull up the data, and stress test your own stance using the 1 key reward and 4 important warning signs.

Looking for more Alumis sized opportunities?

If Alumis has you rethinking risk and reward, do not stop there. Use fresh data driven screens to spot other ideas before the crowd moves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.